TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Indicated for IVF/ICSI in the context of assisted reproductive technology (ART)~* Follow a gonadotropin releasing hormone (GnRH) antagonist protocol, single injection of human chorionic gonadotropin (hCG) for triggering final follicular maturation and luteal phase support with vaginal micronized progesterone.~* Single, fresh D3 or D5 embryo transfer~Key Exclusion Criteria:~* Frozen-thawed embryo transfer~* More than 20 oocytes in the current controlled ovarian hyperstimulation (COH) cycle~* Serum P4 greater than 1.5 ng/mL on the day of hCG administration

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- Nolasiban 900 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Steroids on Post-tonsillectomy Morbidities

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients in the waiting list for tonsillectomy under general anesthesia who accepted to participate in the study.~Exclusion Criteria:~* Patients who are allergic to steroids or those who have medical conditions which contraindicate the use of steroid i.e diabetes mellitus, gastritis, or hypertension and those who were on exogenous steroid supplements.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- IV dexamethasone and oral Prednisolone (Type: EXPERIMENTAL): Single dose of intravenous dexamethasone given immediately following surgery (0.15 mg/kg), followed by oral Prednisolone (0.25mg/kg/day for 7 days then tapering for next 7 days) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).
- Placebo (Type: ACTIVE_COMPARATOR): Placebo (IV saline) and paracetamol (acetaminophen 15 mg/kg/dose every 6 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: European Sickle Cell Disease Cohort - Hydroxyurea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female ambulatory patients, aged 2 years and more (children, adolescents or adults)~* With symptomatic sickle cell syndrome~* Treated with Siklos®~* Having been informed of the study by the initiating physician and consenting to participate to the cohort.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Trial of the FMF Connect Mobile Health Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Biological parent or other primary caregiver (e.g., foster or adoptive parent, relative, legal guardian) of a child with FASD or prenatal alcohol exposure (PAE)~* The parent/caregiver must be at least 18 years old~* The child must between the ages of 3 and 12 years old~* The child has a diagnosis of FASD or has confirmed PAE~* The child has lived with the parent/caregiver for at least 4 months and is expected to remain in the home for at least 1 year~* The parent/caregiver lives in the United States~* The parent/caregiver has a smartphone or ipad with iOS operating system~Exclusion Criteria:~* The parent/caregiver is not fluent in English (the FMF Connect app and pre-post measures are currently only available in English)~* There is another parent/caregiver of the same child or living in the home that is already enrolled in the study (couples are excluded to prevent dependence in the data)~* The family has previously received or is currently receiving the therapist-led Families Moving Forward (FMF) Program

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- FMF Connect Intervention + Coaching (Type: EXPERIMENTAL): Participants receive the FMF Connect mobile health app plus text-based coaching to support continued use of the app and individualized goal setting.
- FMF Connect Intervention (no coaching) (Type: EXPERIMENTAL): Participants receive the FMF Connect mobile health app. They do not receive coaching.
- Waitlist comparison group (Type: NO_INTERVENTION): Participants receive the FMF Connect mobile health app at the conclusion of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- Healthy participants must be non-smokers, normal weight, normal ECG, healthy on the basis of a medical evaluation, physical examination, medical history, ECG, vital signs, and laboratory results~* HCV patients must be of normal weight, normal ECG, chronic genotype 1 HCV infection, non-responders or relapsers to previous treatment regimens and have a HCV viral load at least 50000 IU/mL plasma at screening.~Exclusion Criteria:~* Patients with history of cardiac disease, HIV-1 or HIV-2 test~* Women of childbearing potential~* History or evidence of abuse of alcohol, barbiturate, amphetamine, recreational or narcotic drug use, hepatitis A, B or C infection~* Positive urine drug test~* Any active or underlying disease~* History of drug allergy or hypersensitivity~* Participation in an investigational trial within 30 days prior to the first intake of study medication~* Recent donation of blood~* Abnormal laboratory values~* HCV patients with cardiac disease, co-infections with HIV-1, HIV-2 or liver infection other than HCV~* Women of childbearing potential~* Participants not agreeing to use a reliable birth control method until last trial visit~* Drug abuse~* Cardiovascular, hepatic or renal disease, diabetes, epilepsy, skin or psychiatric disease~* Enrolled in another clinical trial for 90 days prior to screening~* Evidence of Child Pugh B or C liver disease~* Having received a polymerase or protease inhibitor treatment during the last 6 months~* Abnormal laboratory values

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18-74 years (both included) at the time of signing informed consent~* T1DM (Type 1 Diabetes Mellitus) or T2DM (Type 2 Diabetes Mellitus) (as diagnosed clinically) at least 12 months prior to screening~* Daily self-injection(s) with anti-diabetic drug (insulin or Glucagon-Like Peptide-1 (GLP- 1) analogues) in pen-injector or vial/syringe for at least 12 months~* Caucasians~* Body Mass Index (BMI) at least 18.5 kg/m\^2~Exclusion Criteria:~* Known or suspected hypersensitivity to test placebo solution incl. m-cresol and phenol or related products (placebo)~* Female who is pregnant,, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)~* Known urticaria factitive or abnormal reactions to mechanical trauma~* Haemophilia and any diseases affecting blood coagulation~* Anti-coagulant or inhibitors of platelet aggregation treatment on the day of the visit~* Intake of any pain-relieving or analgesic drugs on the day of the site visit~* Skin diseases and infections of the skin in the injection site areas (abdomen and thighs)~* Lipodystrophia in the injection site areas (abdomen and thighs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- DV3316 pen-injector (Type: EXPERIMENTAL): None
- FlexPen® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rural Engagement in Primary Care for Optimizing Weight Reduction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* BMI between 30 kg/m2 and 45 kg/m2.~* Live in a rural location.~* Have clearance from their primary care provider to participate in a diet and exercise weight control intervention.~* Have access to a telephone.~* One individual per household will be permitted to enroll in the study.~Exclusion Criteria:~* History of heart attack in the last six months, stroke in the last six months, or new cancer diagnosis in the last six months.~* History of bariatric surgery or planning bariatric surgery in the next two years.~* Pregnancy within the last six months or planned within the next two years or currently pregnant or lactating.~* Serious medical conditions where weight loss is contraindicated.~* End stage renal disease or end stage liver disease.~* Other medical contraindications as determined by the patient's primary care physician (PCP); documented PCP clearance will be obtained.~* Participants who are already enrolled in, or planning to enroll in another research study where weight loss is targeted.~* Participants who plan to relocate outside of their provider's service area or who plan to leave their primary care clinic in the next 2 years.~* Unable to read and understand English.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fee-for-Service Model (FFS, In clinic individual visits) (Type: ACTIVE_COMPARATOR): Participants will receive individual counseling from their physician or other healthcare professional during regular clinic visits.
- Patient Centered Medical Home (PCMH, In clinic group visits) (Type: ACTIVE_COMPARATOR): Participants will take part in group weight-management counseling during in-person group visits; later sessions may be conducted via group telephone calls if the group prefers.
- Disease Management (DM, Phone group visits) (Type: ACTIVE_COMPARATOR): Participants will take part in group weight-management counseling by telephone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be diagnosed with B-CLL / SLL (B-chronic lymphocytic leukemia / small lymphocytic lymphoma) based on the standard histologic and immunophenotypic criteria described in the WHO classification of lymphoid malignancies, including immunophenotypic confirmation that the tumor cells co-express B cell antigens CD19 / 20 and CD5. Mantle cell lymphoma should be excluded based on positive staining of the tumor cells for CD23, or the absence of staining of the tumor cells for cyclin D1 or the absence of t(11;14).~* The above diagnosis must be confirmed at Brigham \& Women's Hospital or Dana-Farber Cancer Institute.~* Subjects must have relapsed after at least one prior fludarabine-containing regimen and require treatment based on NCI-WG criteria (Appendix A).~* Subjects must have measurable disease (lymphocytosis \> 5,000 / ml, or palpable lymphadenopathy or CT measurable lymphadenopathy \> 1.5 cm, or bone marrow involvement \>30%).~* Men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatment.~* Age \>= 18~* WHO Performance status \<= 2~* Subject has provided written informed consent.~* Expected survival \> 3 months~Exclusion Criteria:~* History of HIV~* Active infection uncontrolled by appropriate antibacterial, antiviral or antifungal therapy~* Known CNS involvement with CLL~* Pregnant (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment) or currently lactating women~* Prior anti-neoplastic therapy within the last three weeks~* Patients will NOT be excluded because they have received prior rituximab or alemtuzumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab & Rituximab (Type: EXPERIMENTAL): Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks)~Rituximab- Given intravenously on day 1 of every week for eight weeks (or 16 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rituximab and ABVD for Hodgkin's Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Hodgkin's disease patients who relapse after radiation therapy alone and previously untreated patients with stage II bulky, III and IV who are eligible for ABVD.~2. Must have histologically proven diagnosis of Hodgkin's disease (Nodular sclerosis or mixed cellularity).~3. Must have bidimensionally measurable disease.~4. Must sign a consent form.~5. Must be older than 16 years of age.~6. Must have adequate bone marrow reserve (ANC \> 1,000/microL, Platelet \> 100,000/microL~7. Left Ventricular Ejection Fraction (LVEF) \>/= 50% by multigated acquisition (MUGA) scan or echocardiogram.~8. Serum creatinine \< 2 mg/dl, serum bilirubin \< 2 mg/dl~Exclusion Criteria:~1. HIV positive.~2. Pregnant women and women of child bearing age who are not practicing adequate contraception.~3. Prior chemotherapy.~4. Severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and asthma.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rituximab + ABVD Chemotherapy (Type: EXPERIMENTAL): Rituximab 375 mg/m\^2 by vein (IV) over 3 to 8 hours weekly for 6 weeks in a row. ABVD Chemo: Adriamycin 25 mg/m\^2 IV, Bleomycin 10 U/m\^2 IV, Vinblastine 6 mg/m\^2 IV, DTIC 375 mg/m\^2 IV. Each but Rituximab over 3 hours every other week for a total of 12 treatments.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Methylphenidate, Dextroamphetamine and Placebo in Children Diagnosed With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age from 9.0 to 14.0.~* ADHD diagnosis following assessment at a child \& adolescent outpatient clinic.~* Clarification for stimulant treatment.~Exclusion Criteria:~* Moderate or severe mental retardation.~* Psychosis.~* Proven brain damage.~* Sensory deficits and/or motor impairments that make the individual in question unsuitable for the relevant tests.~* Epilepsy.~* The child has previously been prescribed stimulant medication or is being treated with such medication.~* The child commutes between parents or there are other factors that substantially reduce the possibility of obtaining reliable observations from parents (The child needs to live in one place through out the whole trial since otherwise might severely influence the child's behaviour and the observations).

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Methylphenidate, Dexamphetamine, Placebo (Type: EXPERIMENTAL): The 36 participants received each of the three medications for two weeks. Six different medication sequences are possible. The participants are randomly chosen for each of the six sequences in a way that allow six participants into each of the six sequences to balance the sequences.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with ADHD only or ADHD and Dyslexia~* At least 10 years old and no more than 16 years old~* IQ score of 80 or more~* Must be able to swallow capsules~Exclusion Criteria:~* Have received treatment within last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry~* Weigh less than 25 kg or greater than 70 kg~* Pregnant or breast feeding~* Documented history of bipolar I or II disorder, or psychosis~* Documented history of autism, Asperger's syndrome or pervasive developmental disorder

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-label, Multinational, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with epilepsy who participated in previous brivaracetam trials which allow access to the present trial.~* Subjects from whom the Investigator believes a reasonable potential benefit from the long-term administration of brivaracetam may be expected.~Exclusion Criteria:~• Severe medical, neurological and psychiatric disorders, including current suicidal ideation or behaviour, or laboratory values which may have an impact on the safety of the subject, as determined by the investigator.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brivaracetam (Type: EXPERIMENTAL): Brivaracetam at flexible dosing up to 200mg /day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rasburicase in Patients at Risk for Tumor Lysis Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with hematological malignancies (leukemia/lymphoma) at high risk or potential risk for tumor lysis syndrome. High risk: hyperuricemia of malignancy (Uric acid levels \>7.5); diagnosis of very aggressive lymphoma/leukemia based on Revised European-American Lymphoma (REAL) classification; acute myeloid leukemia, chronic myelocytic leukemia (CML) in blast crisis; high grade myelodysplastic syndrome only if they have \>10% bone marrow blast involvement and given aggressive treatment similar to acute myeloid leukemia (AML) (continued on #2)~2. (continued from # 1) Potential risk: diagnosis of aggressive lymphoma/leukemia based on (REAL) classification. Plus one or more of the following criteria: lactate dehydrogenase (LDH) \>/= 2 x upper limit of normal (ULN); Stage III-IV disease; Stage I-II disease with at least 1 lymph node/tumor \>5cm in diameter.~3. ECOG performance status 0-3~4. Life expectancy \>3 months~5. Negative pregnancy test (females of child bearing potential) within \</=2 weeks of rasburicase dose and use of efficient contraceptive method (both males and females). Pregnancy test may be performed on serum (HCG) or urine (HCG)~6. Signed written informed consent (approved by the Institutional Review Board/Ethics Committee) obtained prior to study entry~Exclusion Criteria:~1. Patient receiving any investigational drug for hyperuricemia within 30 days of planned first treatment with rasburicase~2. Pregnancy or lactation~3. Known history of significant allergy problem or documented history of asthma or asthmatic bronchitis~4. Known history of glucose-6-phosphate dehydrogenase deficiency~5. Known history of hemolysis and methemoglobinemia~6. Previous therapy with urate oxidase~7. Other conditions unsuitable for participation in the trial in the Investigator's opinion~8. Unwillingness to comply with the requirements of the protocol~9. Use of allopurinol within 72 hours of the study entry

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): As Needed Rasburicase .15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
- Group B (Type: EXPERIMENTAL): Fixed Dose Rasburicase .15 mg/kg IV Over 30 Minutes Daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete